Xeltis

Today, Xeltis will be presenting promising 12-month patency data from the First-In-Human clinical study of its Coronary Artery Bypass Conduit, #XABG, at the EACTS - European Association for Cardio-Thoracic Surgery Annual Meeting 2024.   📅 Thursday, 10 October | 🕔 14:45 - 15:15 CEST | 📍 Theatre 1   World leading cardiothoracic surgeon Isaac George M.D., FACC, FACS, will present the data, which will showcase promising patency rates, suggesting the potential for the long-term durability of XABG, potentially eliminating the need for vein harvesting and transforming the bypass surgery landscape.   XABG is a novel, biorestorative, polymeric conduit with an embedded microskeleton. XABG has unique regenerative properties, enabling living tissue to replace it over time.   You can see the full details of the presentation in EACTS programme linked in the comments below.   #EACTS2024 #vascularsurgery

Last week was action-packed for the Xeltis team with multiple presentations at prestigious conferences! Our Co-Founder, Martijn Cox, along with Hannah Bauer, Preclinical Development Scientist, presented at The International Society for Applied Cardiovascular Biology (ISACB) 19th Biennial Meeting in Vienna. Meanwhile, on Saturday morning, Robert Shahverdyan, MD 🇦🇲🇩🇪, Head of Vascular Access Centre Hamburg and renowned KOL, presented on our vascular access conduit, #aXess, at the Controversies in Dialysis Access (CiDA) Symposium in Washington, DC. We are deeply grateful for the opportunity to highlight our innovative work at Xeltis, as we continue pushing boundaries in vascular access space. #CiDA #ISACB #VascularAccess

The Xeltis team had the privilege of hosting a dinner with world renowned specialists in the vascular access space.   Our CEO, Eliane Schutte, VP Clinical Business Development, Luc Verhees, and VP of Clinical Affairs, Shawn M. Gage, PA-C, were joined by these leading KOLs, to engage in dynamic discussions that provided invaluable insights for the future of Xeltis.   The expertise and perspectives shared were invaluable as we explore the next steps in advancing our US pivotal trial for #aXess, following the recent IDE approval from the FDA.   We extend our sincere thanks to those who joined us and contributed to this exciting chapter for Xeltis.   Stephen Hohmann, Daniel Patel, Karl Illig, Eric Peden, Robert Shahverdyan, MD 🇦🇲🇩🇪, John Lucas III, Ari Kramer, Jason Burgess

Xeltis are looking forward to attending and presenting at The International Society for Applied Cardiovascular Biology (ISACB) 19th Biennial Meeting in Vienna from October 5 - 8. The details of the presentations are as follows: XABG: A Restorative Polymeric Coronary Artery Bypass Conduit  💬Session 2: Pre-clinical Novelties in Vascular Tissue Engineering 👤Martijn Cox, Co-Founder 📅 Saturday, 5 October | 🕔 15:00 - 17:10 CEST Rat infection model supports improved infection resistance of restorative aXess conduits compared to ePTFE controls  💬Session 11: Cardiac and Vascular Remodeling 👤Hannah Bauer, Preclinical Development Scientist 📅 Tuesday, 8 October | 🕔 08:30 - 10:30 CEST Clinical translation of Restorative Vascular Conduits: Update on progress and insights 💬Session 12: New Opportunities and Challenges in Translational Innovation  👤Martijn Cox, Co-Founder 📅 Tuesday, 8 October | 🕔 11:00 - 12:30 CEST Make sure to come along to these insightful presentations or get in touch if you would like to meet a member of the team! #vascularaccess #dialysis #ISACB

This week, from October 3-5, Xeltis will be attending the Controversies in Dialysis Access (CiDA) Symposium in Washington, DC. This meeting brings together Surgeons, Nephrologists, Interventional Radiologists, and dialysis staff to share insights and experiences on the complexities of vascular access for dialysis. By listening to diverse perspectives, this symposium explores key challenges and advances in dialysis treatments, improving care for patients. Leading KOL Dr Robert Shahverdyan, MD 🇦🇲🇩🇪 will be presenting at the conference! 🎤 Innovative Breakthroughs in Dialysis: A Novel Restorative Conduit for Dialysis Access 📅Saturday, 5 October 🕔9:12 AM - 9:20 AM PDT We’re excited to join the conversation and share the Xeltis mission of addressing unmet medical needs to enhance the lives of patients worldwide. #CiDA2024 #Dialysis #VascularAccess

This Sunday is #WorldHeartDay and Xeltis is proud to support the World Heart Federation's global campaign to raise awareness about the importance of heart health ❤️🌎 Cardiovascular disease (#CVD) is the leading cause of death globally, and combined with heart attacks, strokes, and heart failure, these conditions claim more than 20.5 million lives every year.   At Xeltis, we're leveraging Nobel prize-backed science to pioneer innovative restorative vascular implants addressing this critical unmet medical need, improving the lives of patients worldwide.   Our coronary bypass conduit, XABG, has unique regenerative properties, enabling living tissue to replace it over time. Now in a first-in-human study, XABG has the potential to transform the bypass surgery landscape, eliminating the need for vein harvesting, easing the burden on patients, and reducing the immense strain on global healthcare systems.   Learn more about how we are reshaping the treatment of cardiovascular disease and other areas of high unmet need using the link in the first comment below.

This week Xeltis will be attending the European Society for Vascular Surgery Annual Meeting from 24 - 27 September in Kraków, Poland. We are looking forward to connecting with world-renowned vascular surgeons, researchers, and practitioners, while participating in hands-on workshops, thought-provoking keynote speeches and engaging in discussions that are shaping the future of vascular surgery. CMO Paulo Neves will be in attendance, alongside Senior R&D Manager Wian van den Bergh and R&D Engineer Bilal Enes Okatar. Be sure to reach out to a member of the team to learn more about our transformative implants! #ESVS2024 #VascularSurgery

See our CEO, Eliane Schutte, this week at LSI Europe where she participated in a panel session and delivered a company presentation.   On Tuesday, Eliane joined the panel 'The Art and Science of Cross-Border Business Development and Licensing' sharing her expertise alongside top industry leaders in a thought-provoking discussion.   On Wednesday, she delivered an in-depth presentation on Xeltis, highlighting our transformative vascular implants and how they support the natural development of living, long lasting tissue - showcasing our innovative approach to addressing a large unmet clinical need.   It’s been an incredible week of insightful panels, discussions, and networking at LSI!   #LSIEurope #Medtech

See our CFO Alexander Goemans yesterday at LSI Europe during his 'Building Syndicates of Cross-Border Investors in Medtech Companies' panel.   It has been fantastic so far to listen and contribute to such high-level conversations with industry leaders in the medtech field.   We are excited to see what the rest of the week brings - if you are also in attendance and would like to connect with Alexander and our CEO Eliane Schutte, please reach out!   #LSIEurope24 #medtech

The countdown to LSI Europe is on - just one week left until I’ll be in Portugal representing @Xeltis alongside our CEO, Eliane Schutte.   I will be sharing my insights during a panel session: 🎤 Building Syndicates of Cross-Border Investors in Medtech Companies 📅 17 September ⌚ 15:45 - 16:25 CEST   If you'd like to connect directly, don’t hesitate to reach out!   #LSIEurope2024